Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Adlai Nortye Ltd. American Depositary Shares (ANL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: ANL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.84% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.35M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 1.10 - 4.10 | Updated Date 07/2/2025 |
52 Weeks Range 1.10 - 4.10 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1220.88% |
Management Effectiveness
Return on Assets (TTM) -32.84% | Return on Equity (TTM) -103.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21667401 | Price to Sales(TTM) 28.53 |
Enterprise Value 21667401 | Price to Sales(TTM) 28.53 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA - | Shares Outstanding 31236900 | Shares Floating 59847067 |
Shares Outstanding 31236900 | Shares Floating 59847067 | ||
Percent Insiders 14.25 | Percent Institutions 0.18 |
Analyst Ratings
Rating 1 | Target Price 9 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Adlai Nortye Ltd. American Depositary Shares
Company Overview
History and Background
Adlai Nortye Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative oncology therapies. Founded in 2007, it aims to address unmet medical needs in cancer treatment.
Core Business Areas
- Drug Development: Research and development of novel oncology drugs, focusing on innovative mechanisms of action.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Bringing approved drugs to market and establishing commercial partnerships.
Leadership and Structure
The leadership team comprises experienced executives in pharmaceutical research, development, and commercialization. The company structure includes research, clinical development, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- AN2025 (buparlisib): A pan-PI3K inhibitor in clinical development for various cancers. It is currently in Phase III trials. Market share is not yet applicable as it's not approved. Competitors include other PI3K inhibitors from companies like Novartis and Bayer.
- AN0025: A small molecule multi-kinase inhibitor in clinical trials. Market share is not yet applicable as it's not approved. Competitors include other multi-kinase inhibitors from companies like Pfizer and Bayer.
Market Dynamics
Industry Overview
The oncology drug market is large and growing, driven by increasing cancer incidence and advancements in treatment options. The industry is characterized by intense competition and high R&D costs.
Positioning
Adlai Nortye Ltd. aims to establish a competitive position through innovative drug candidates and strategic partnerships. Its advantage lies in its focus on novel mechanisms of action.
Total Addressable Market (TAM)
The global oncology market is estimated to reach over $300 billion in the coming years. Adlai Nortye Ltd. aims to capture a portion of this market with its pipeline of drug candidates.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline
- Experienced management team
- Strategic partnerships
- Focus on unmet medical needs
Weaknesses
- High R&D costs
- Dependence on clinical trial outcomes
- Competition from established pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Expansion into new markets
- Strategic acquisitions
- Partnerships with larger pharmaceutical companies
- Approval and commercialization of drug candidates
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from biosimilars
- Economic downturns
Competitors and Market Share
Key Competitors
- NVS
- BAYRY
- MRK
Competitive Landscape
Adlai Nortye Ltd. faces competition from established pharmaceutical companies with larger resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Growth trends depend on clinical trial progress and strategic partnerships.
Future Projections: Future growth depends on successful clinical trials and commercialization of drug candidates.
Recent Initiatives: Focus on advancing clinical trials and securing partnerships.
Summary
Adlai Nortye Ltd. is a biopharmaceutical company with a promising pipeline of oncology drugs and a focus on innovative mechanisms. Its success hinges on positive clinical trial results and the ability to secure strategic partnerships. High R&D costs and competition pose significant challenges. Securing funding will be important for continued growth and success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The data and analysis provided are based on publicly available information and industry reports. It should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adlai Nortye Ltd. American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-09-29 | Co- Founder, CEO & Chairman Mr. Yang Lu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.adlainortye.com |
Full time employees 123 | Website https://www.adlainortye.com | ||
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.